Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018

Article

The ONCOLOGY team invites you to attend a meet and greet event with our team and members of our expert Advisory Board at the 60th American Society of Hematology (ASH) 2018 meeting in San Diego, California. Appetizers and drinks will be served!

Meet the following hematology/oncology experts:

  • Julie M. Vose, MD, MBA, FACP, FASCO
  • John Sweetenham, MD, FRCP
  • Stephen T. Rosen, MD

Event Details

Date: Saturday, December 1, 2018

Time: 2:00 PM to 3:00 PM

Location: Booth #3011 in the San Diego Convention Center Exhibit Hall
 

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content